A new non-surgical treatment for low-risk prostate cancer can effectively kill cancer cells while preserving healthy tissue, reports a new UCL-led phase III clinical trial in 413 patients. The trial was funded by STEBA Biotech which holds the commercial license for the treatment. (more…)
Researchers at UCLA’s Jonsson Comprehensive Cancer Center have developed a way to image the spread of a dangerous form of prostate cancer earlier than today’s conventional imaging techniques. The new method may allow oncologists to find and treat metastases more quickly and give patients a better chance at survival.
The gene-based imaging system targets castration-resistant prostate cancer, an aggressive form of the disease that has become resistant to the hormone treatment known as androgen-deprivation therapy. Once this treatment no longer works, the cancer will progress within 12 to 18 months, and the prognosis becomes grim, said senior study author Dr. Lily Wu, a professor of molecular and medical pharmacology and a Jonsson Cancer Center researcher. (more…)
